Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Valirx Plc LSE:VAL London Ordinary Share GB00BLH13C52 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 20.75 20.50 21.00 20.75 20.75 20.75 417,594 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -2.7 -0.3 - 13

Valirx Share Discussion Threads

Showing 24151 to 24172 of 24425 messages
Chat Pages: 977  976  975  974  973  972  971  970  969  968  967  966  Older
DateSubjectAuthorDiscuss
16/2/2021
11:29
Spreadex let me add
dope007
16/2/2021
11:15
I tried to add at 22p but had not quote with ig
jungmana
16/2/2021
11:09
It’s hit it’s recent lows this morning not everyone’s impatient and as shown will buy on the dips.
412069
16/2/2021
11:04
Arab , am still here and in good profit .I can wait for that deal even if it takes a year from now
jungmana
16/2/2021
11:01
Yourself Jungmana ?
arab3
16/2/2021
10:58
I feel we may revisit 19p again. Some investors loosing patience imo
jungmana
16/2/2021
10:27
Buys coming in my first page is all blue now, a bit miffed that you can still get these cheaper than my last top up which was rock bottom grrrr
bobaxe1
16/2/2021
10:22
The big boys are still holding that’s my rule and they must think 14m Mcap is still cheap.
412069
16/2/2021
10:09
I've just about reached that point myself
nmulm
16/2/2021
09:52
Yes and sellers getting fed up of waiting, expecetd somehing by now with all the data out now
joeblogg2
15/2/2021
09:09
Hi Nico Thoughts on rns?
jasonpugh
15/2/2021
09:09
You don't sign a contract paying upto £6m for 10 months work unless you are very confident that you will make that and some. Great news
tburns
15/2/2021
08:13
15 February 2021 ("ValiRx", the "Company" or the "Group") Extension of Collaboration Agreement London, UK - ValiRx plc (AIM:VAL), a clinical stage drug development company, announces today that it has entered into a new agreement with Physiomics plc ("Physiomics")(AIM:PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The new agreement supersedes the agreement between Physiomics and the Group which was announced on 13 September 2011. Under the terms of the new agreement, ValiRx will benefit from Physiomics' experience in modelling the effects of prostate cancer treatment, as well the use of the latest version of its Virtual Tumour(TM) technology, which will be applied to derive valuable information from the additional data generated by the completed clinical trial of VAL201. Physiomics will also support ValiRx in modelling the use of the VAL201 peptide in endometriosis (VAL301) and Coronavirus (BC201). Physiomics has developed a quantitative systems pharmacology approach that uses pre-clinical and clinical data to model the activity of a drug candidate. This data can be used to explore the mechanism of action, disease impact and optimal dosing strategies. Physiomics will receive a fee (capped at GBP6m) of 6% of any future net revenues that may be received by ValiRx relating to its commercialisation of VAL201 and its derivatives in any indication, including prostate cancer, endometriosis and treatment for Coronavirus infection. Eligibility for part of this fee will be conditional on completion of an agreed program of work by Physiomics that builds on the work already carried out under the 2011 agreement. This program of work will start on 15 February 2021 and is required to be carried out by 15 November 2021. In recognition of the collaborative nature of this new agreement, Physiomics will also be offered a seat on the ValiRx scientific advisory board. Dr Suzy Dilly, Chief Executive Officer of ValiRx, commented: "I am pleased to be able to expand our collaboration and the scope of work being carried out by Physiomics. Enhancing the scientific understanding of our results using cutting edge technology ensures we maximise the value of the data we have collected. This will help in the design and execution of future clinical trials and support discussions with potential new partners. We expect that outputs from the application of Physiomics' technology will be incorporated into scientific publications presenting the results from the VAL201 clinical trial." Dr Jim Millen, Chief Executive Officer of Physiomics, added: "We are delighted to be working once again with ValiRx on a programme of work that replaces and extends that originally agreed in 2011. Since the time of the original agreement, Physiomics has gained significant additional experience in the modelling of prostate and other cancers and we will be aiming to generate new insights which can improve development outcomes." This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. The Directors of the Company take responsibility for this announcement. Ends
thebossman
15/2/2021
07:29
RNS - Good deal for both and Suzy appears very confident of data analysis proving up benefits and efficacy of 201. Dr Suzy Dilly, Chief Executive Officer of ValiRx, commented: "I am pleased to be able to expand our collaboration and the scope of work being carried out by Physiomics. Enhancing the scientific understanding of our results using cutting edge technology ensures we maximise the value of the data we have collected. This will help in the design and execution of future clinical trials and support discussions with potential new partners. We expect that outputs from the application of Physiomics' technology will be incorporated into scientific publications presenting the results from the VAL201 clinical trial."
tburns
15/2/2021
07:27
6% = 6m someone’s valued the whole project when complete at 100m.
412069
12/2/2021
16:10
Ok mm I've sold you win ave em cheap
bobaxe1
12/2/2021
11:13
So blue sells now
bobaxe1
11/2/2021
15:16
Buying started again, rumblings
bobaxe1
11/2/2021
09:34
Same tactic as yesterday early dip followed by a rise later.
412069
10/2/2021
16:42
anytime this week will do me Bob. GLA
tburns
10/2/2021
16:00
Tomorrow then
bobaxe1
10/2/2021
13:27
Next level please Mr nice mm
bobaxe1
Chat Pages: 977  976  975  974  973  972  971  970  969  968  967  966  Older
ADVFN Advertorial
Your Recent History
LSE
VAL
Valirx
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210412 02:00:19